Correlation Between Checkpoint Therapeutics and X4 Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Checkpoint Therapeutics and X4 Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Checkpoint Therapeutics and X4 Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Checkpoint Therapeutics and X4 Pharmaceuticals, you can compare the effects of market volatilities on Checkpoint Therapeutics and X4 Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Checkpoint Therapeutics with a short position of X4 Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Checkpoint Therapeutics and X4 Pharmaceuticals.

Diversification Opportunities for Checkpoint Therapeutics and X4 Pharmaceuticals

-0.79
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Checkpoint and XFOR is -0.79. Overlapping area represents the amount of risk that can be diversified away by holding Checkpoint Therapeutics and X4 Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on X4 Pharmaceuticals and Checkpoint Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Checkpoint Therapeutics are associated (or correlated) with X4 Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of X4 Pharmaceuticals has no effect on the direction of Checkpoint Therapeutics i.e., Checkpoint Therapeutics and X4 Pharmaceuticals go up and down completely randomly.

Pair Corralation between Checkpoint Therapeutics and X4 Pharmaceuticals

Given the investment horizon of 90 days Checkpoint Therapeutics is expected to generate 0.3 times more return on investment than X4 Pharmaceuticals. However, Checkpoint Therapeutics is 3.36 times less risky than X4 Pharmaceuticals. It trades about 0.12 of its potential returns per unit of risk. X4 Pharmaceuticals is currently generating about 0.02 per unit of risk. If you would invest  384.00  in Checkpoint Therapeutics on August 30, 2024 and sell it today you would earn a total of  44.00  from holding Checkpoint Therapeutics or generate 11.46% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Checkpoint Therapeutics  vs.  X4 Pharmaceuticals

 Performance 
       Timeline  
Checkpoint Therapeutics 

Risk-Adjusted Performance

19 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Checkpoint Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Checkpoint Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.
X4 Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days X4 Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Checkpoint Therapeutics and X4 Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Checkpoint Therapeutics and X4 Pharmaceuticals

The main advantage of trading using opposite Checkpoint Therapeutics and X4 Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Checkpoint Therapeutics position performs unexpectedly, X4 Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will offset losses from the drop in X4 Pharmaceuticals' long position.
The idea behind Checkpoint Therapeutics and X4 Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Complementary Tools

Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Bonds Directory
Find actively traded corporate debentures issued by US companies